Use of Targeted Cancer Drugs for Lung Cancer in Germany
Author Information
Author(s): Nikolaj Rischke, Josephine Kanbach, Ulrike Haug
Primary Institution: Leibniz Institute for Prevention Research and Epidemiology – BIPS
Hypothesis
What is the real-world utilization of targeted cancer drugs requiring molecular tumor diagnostics in lung cancer patients in Germany?
Conclusion
Only 5% of lung cancer patients diagnosed in 2016 in Germany received at least one targeted therapy, with higher rates in East Germany compared to West Germany.
Supporting Evidence
- 5% of lung cancer patients diagnosed in 2016 received targeted therapy.
- 62% of patients treated with targeted drugs were female.
- Median overall survival after the first targeted therapy was 22 months.
- 30.2% of all patients had at least one code for molecular tumor diagnostics.
- Proportion of patients treated with targeted drugs was higher in East Germany (6.2%) than in West Germany (4.8%).
Takeaway
Out of every 20 lung cancer patients in Germany, only 1 got special drugs that help fight their cancer. More patients in East Germany got these drugs than in West Germany.
Methodology
The study analyzed claims data from the GePaRD database, identifying lung cancer patients diagnosed in 2016 and following them until 2019 to assess drug utilization.
Potential Biases
Potential underreporting of molecular diagnostics due to lack of specific coding in claims data.
Limitations
The study relies on claims data, which may lack detailed information on cancer staging and histology.
Participant Demographics
Mean age at diagnosis was 69 years, with 44.8% female and 71.7% diagnosed at an advanced stage.
Statistical Information
Confidence Interval
95% CI 4.5–5.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website